IZOZF - Izotropic Launches Marketing Campaign
(TheNewswire)
VANCOUVER, BC – TheNewswire – March 18, 2021 – IzotropicCorporation (“ Izotropic ”)(CSE: IZO ) (OTC: IZOZF ) (FSE: 1R3 ) (CNSX:IZO.CN) , a company developinghigh-resolution 3D dedicated breast CT imaging technology for theearlier detection and diagnosis of breast cancers, announces is hasbegun USA focused marketing awareness aimed at maintaining andbuilding the profile of IZOZF through press initiatives, advertising,and social media strategies.
As part of these marketing plans, Izotropic has engagedwith ThinkInk Marketing Inc., an arm's-length party to the company, toprovide a 12-month digital advertising campaign designed to buildrecognition within online investor content platforms. Izotropic hasallocated USD $250,000 to its scalable advertising budget. ThinkInkMarketing Inc. has no present interest, directly or indirectly, inIzotropic or its securities.
Izotropic has also ramped up the content flow on socialmedia channels and is pleased to report an over 200% increase intraffic to its website in the past month and positive engagement fromnew investors through email drip campaign activities.
ON BEHALF OF THE BOARD
For investor relations inquiriescontact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
About Izotropic Corporation
Izotropic Corporation is commercializing dedicatedbreast CT imaging technology for the earlier detection, diagnosis andtreatment of breast cancers. Extensive preliminary studies have foundthat breast CT may be able to routinely detect small breast tumors inthe 3-5 mm size range. The median size of breast cancer found usingmammography is approximately 11 mm. Routine detection of 3 mm lesionswould result in 1.5 year earlier detection over mammography.
The initial indication for use for breast CT as adiagnostic device has been confirmed. Forthcoming business objectivesinclude identifying additional indications for use, development ofaccessories, and additional products, all aimed at making breast CT anindispensable tool for improving the outcomes of breast cancer.
Additional information about Izotropic Corporation canbe found on its website at izocorp.com and by reviewing itsprofile on SEDAR at sedar.com
Forward-Looking Statements
This document may contain statements that are“Forward-Looking Statements,” which are based upon the currentestimates, assumptions, projections and expectations of thecompany’s management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify such information and statements byusing words such as “anticipate,” “believe,” “envision,”“estimate,” “expect,” “intend,” “may,” “plan,”“predict,” “project,” “target,” “potential,”“will,” “would,” “could,” “should,” “continue,”“contemplate” and other similar expressions and derivationsthereof in connection with any discussion of future events, trends orprospects or future operating or financialperformance, although not all forward-looking statements contain theseidentifying words. These statements are not guarantees of performanceand involve risks and uncertainties that are difficult to control orpredict, and as such they may cause future results of the company’sactivity to differ significantly from the content and implications ofsuch statements. Forward-Looking Statements are pertinent only as ofthe date on which they are made, and the company undertakes noobligation to update or revise any Forward-Looking Statements toreflect new information or the occurrence of future events orcircumstances unless otherwise required to do so by law. Neither the company nor its shareholders, officers andconsultants, shall be liable for any action and the results of anyaction taken by any person based on the information contained herein,including without limitation the purchase or sale of companysecurities. Nothing in this document should be deemed to be medical orother advice of any kind.
Copyright (c) 2021 TheNewswire - All rights reserved.